{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:56:50Z","timestamp":1762955810540},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T00:00:00Z","timestamp":1507852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T00:00:00Z","timestamp":1507852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Astellas Pharma, Inc. and Medivation, Inc., which was acquired by Pfizer, Inc. in September 2016, the co-developers of enzalutamide"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40261-017-0578-0","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T05:23:40Z","timestamp":1507872220000},"page":"1183-1190","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Risk Factors for and Incidence of Seizures in Metastatic Castration-Resistant Prostate Cancer: A Real-World Retrospective Cohort Study"],"prefix":"10.1007","volume":"37","author":[{"given":"Charles","family":"Dharmani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Machaon","family":"Bonafede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Krivoshik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,13]]},"reference":[{"key":"578_CR1","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/pros.21263","volume":"71","author":"WR Foster","year":"2011","unstructured":"Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate. 2011;71:480\u20138.","journal-title":"Prostate"},{"key":"578_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.eururo.2015.01.026","volume":"68","author":"CS Higano","year":"2015","unstructured":"Higano CS, Beer TM, Taplin ME, Efstathiou E, Hirmand M, Forer D, et al. Long-term safety and antitumor activity in the phase 1\u20132 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer. Eur Urol. 2015;68:795\u2013801.","journal-title":"Eur Urol"},{"key":"578_CR3","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","volume":"375","author":"HI Scher","year":"2010","unstructured":"Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study. Lancet. 2010;375:1437\u201346.","journal-title":"Lancet"},{"key":"578_CR4","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","volume":"15","author":"B Tombal","year":"2014","unstructured":"Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol. 2014;15:592\u2013600.","journal-title":"Lancet Oncol"},{"key":"578_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"578_CR6","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","volume":"34","author":"DF Penson","year":"2016","unstructured":"Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol. 2016;34:2098\u2013106.","journal-title":"J Clin Oncol."},{"key":"578_CR7","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"578_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","volume":"17","author":"ND Shore","year":"2016","unstructured":"Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016;17:153\u201363.","journal-title":"Lancet Oncol"},{"key":"578_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/B978-012621355-3\/50014-1","volume-title":"The comprehensive evaluation and treatment of epilepsy","author":"EB Bromfield","year":"1997","unstructured":"Bromfield EB. Epilepsy and the elderly. In: Schachter SC, Schomer DL, editors. The comprehensive evaluation and treatment of epilepsy. San Diego: Academic Press; 1997. p. 233\u201354."},{"key":"578_CR10","unstructured":"Slovin S, Clark W, Carles J, Krivoshik A, Park JW, Wang F, et al. Seizure rates in enzalutamide-treated men with metastatic castration-resistant prostate cancer and increased risk of seizure: the UPWARD study. Jama Oncol. (in press)."},{"key":"578_CR11","first-page":"143","volume":"10","author":"D Pilon","year":"2017","unstructured":"Pilon D, Behl AS, Ellis LA, Robitaille MN, Lefebvre P, Dawson NA. Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy. Am Health Drug Benefits. 2017;10:143\u201353.","journal-title":"Am Health Drug Benefits"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-017-0578-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0578-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0578-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T07:44:08Z","timestamp":1650872648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-017-0578-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,13]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["578"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0578-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,13]]},"assertion":[{"value":"13 October 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not report on any studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Charles Dharmani is an employee of Astellas. Machaon Bonafede is an employee of Truven Health Analytics, an IBM Company, which was awarded a research contract to conduct this study with and on behalf of Astellas Pharma, Inc. Andrew Krivoshik is an employee of Astellas and holds stock in AbbVie and Abbott.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was funded by Astellas Pharma, Inc. and Medivation, Inc., which was acquired by Pfizer, Inc. in September 2016, the co-developers of enzalutamide. Medical writing assistance and editorial support, funded by both sponsor companies, was provided by Mei Lye and Lauren Smith from Complete HealthVizion.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}